Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN) gapped up before the market opened on Friday . The stock had previously closed at $25.61, but opened at $26.42. Dyne Therapeutics shares last traded at $25.71, with a volume of 40,896 shares.

Analyst Ratings Changes

A number of equities analysts have weighed in on DYN shares. Piper Sandler restated an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 target price for the company. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.42.

Dyne Therapeutics Stock Down 0.2 %

The company’s fifty day moving average is $30.53 and its two-hundred day moving average is $35.24. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -7.19 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Activity

In related news, insider Oxana Beskrovnaya sold 2,334 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now directly owns 201,685 shares in the company, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares in the company, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 180,046 shares of company stock valued at $6,300,265 in the last ninety days. 20.77% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its position in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $34,000. Point72 DIFC Ltd purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $36,000. US Bancorp DE boosted its position in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth $62,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.